A cohort study of therapeutic prescriptions after the end of phytotherapy drug reimbursement by French Social Security
Authors:
- 4 December 2012
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 22 (7) , 760-768
Abstract
Purpose The reimbursement of phytotherapy drugs for the treatment of mild anxiety and insomnia ended in March 2006 in France. The aim of this study is to investigate the short-term impact of stopping phytotherapy reimbursement. Methods We monitored the prescriptions of 27 422 patients who received hypnotic and sedative phytotherapy drug treatment at least once in the 12 months preceding the end of reimbursement and made contact with their prescribing physician at least once in the following 12 months. A control cohort was recruited from patients fulfilling the same inclusion criteria in the 24 months before de-reimbursement and their prescriptions in the following 12 months were monitored. The impact of the end of reimbursement is estimated comparing prescription switches in these cohorts. Results Before the end of reimbursement, 7684 (28%) patients being prescribed delisted phytotherapy drugs had the relevant drug marketing authorization approval (DMAA) indications. Co-prescriptions of hypnotic and sedative drugs concerned 40% of patients. Of the 4646 DMAA patients exclusively prescribed phytotherapy, 640 (14%) switched to hypnotic or sedative drugs only after the end of reimbursement, 3266 (70%) stopped all treatments and 740 (16%) carried on with a non-reimbursed phytotherapy prescription. When compared to the control cohort, patients exposed to de-reimbursement were more likely to switch to psychotropic drugs (OR = 1.46). Conclusions Ending the reimbursement of common drugs on the basis of insufficient evidence regarding their effectiveness or the low level of severity of their target pathologies should be accompanied by information or advice to prescribing health care actors. Copyright © 2012 John Wiley & Sons, Ltd.Keywords
This publication has 14 references indexed in Scilit:
- Reimbursement Restriction and Moderate Decrease in Benzodiazepine Use in General PracticeThe Annals of Family Medicine, 2012
- Frequency and circumstances of placebo use in clinical practice - a systematic review of empirical studiesBMC Medicine, 2010
- The influence of prescription drug insurance on psychotropic and non-psychotropic drug utilization in CanadaSocial Science & Medicine, 2007
- Efficacy and Tolerability of a Standardized Herbal Product from Galphimia glauca on Generalized Anxiety Disorder. A Randomized, Double-Blind Clinical Trial Controlled with LorazepamPlanta Medica, 2007
- A systematic review of valerian as a sleep aid: Safe but not effectiveSleep Medicine Reviews, 2007
- Stellungnahme der Kommission "Qualität und Transparenz von Phytopharmaka"Complementary Medicine Research, 2007
- Do Herbal Agents Have a Place in the Treatment of Sleep Problems in Long-Term Care?Journal of the American Medical Directors Association, 2007
- Étude des reports de prescription : objectifs, méthodes et limitesTherapies, 2007
- Is there clinical evidence supporting the use of botanical dietary supplements in children?The Journal of Pediatrics, 2005
- Alternative Medicine — The Case of Herbal RemediesNew England Journal of Medicine, 1999